learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
Search
forLearn
5 / 801 resultslearn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn enoxolone
learn retinoic acid
learn phenoxyethanol
Research
5 / 486 results
research Search for New antineoplastic agents based on structural modifications of steroidal 5α-reductase, 17β-hydroxysteroid dehydrogenase, and 17α-hydroxylase/17,20-lyase inhibitors
Modifying steroidal inhibitors shows promise for developing new cancer treatments.
research Drug-Induced Hair Loss and Hair Growth
Some drugs can cause hair loss or increase hair growth, but these effects are usually reversible when the drug is stopped.
research DRUG‐ASSOCIATED ALOPECIA
Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.
research When bugs and drugs conspire: driving acneiform skin toxicity
Certain cancer drugs interact with skin bacteria to cause acne-like rashes.
research 1P-230: Synthesis and in vitro characterization of 68 Ga labeled Fe 3 O 4 nanoparticles for drug delivery
The nanoparticles show promise for cancer treatment and diagnosis with fewer side effects.
Community Join
5 / 1000+ resultscommunity Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community OND-1 "Cyclosporine A” New hair loss treatment
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.